Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors

Masanori Hayashi, David M. Loeb, Allen R. Chen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The prognosis for recurrent or refractory pediatric solid tumors such as neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, germ cell tumor, osteosarcoma, and Ewing sarcoma is dismal, and few patients have experienced prolonged survival. Most pediatric solid tumor patients are treated with intensive chemotherapy, and most recurrences occur during treatment or within 1 year of its completion. For agents such as melphalan, carmustine, and carboplatin, whose major dose limiting toxicity is myelosuppression, hematopoietic cell transplantation (HCT) may permit 3-10-fold dose escalation. The recognition that patients with bilateral retinoblastoma are at increased risk of developing osteosarcoma implicates the RB1 gene in the pathogenesis of osteosarcoma. The role of allogeneic HCT in pediatric solid tumors is being explored. Allogeneic transplantation carries the risk of graft-versus-host disease (GVHD), but its potential benefits include the absence of tumor cells in the graft and perhaps an immunologic antitumor effect.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
PublisherWiley Blackwell
Pages768-784
Number of pages17
Volume2-2
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Cell Transplantation
Osteosarcoma
Pediatrics
Retinoblastoma
Neoplasms
Carmustine
Ewing's Sarcoma
Melphalan
Wilms Tumor
Rhabdomyosarcoma
Germ Cell and Embryonal Neoplasms
Carboplatin
Homologous Transplantation
Graft vs Host Disease
Neuroblastoma
Transplants
Recurrence
Drug Therapy
Survival
Genes

Keywords

  • Desmoplastic small round cell tumor
  • Ewing sarcoma
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Neuroblastoma
  • Osteosarcoma
  • Pediatric solid tumors
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms tumor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hayashi, M., Loeb, D. M., & Chen, A. R. (2016). Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition (Vol. 2-2, pp. 768-784). Wiley Blackwell. https://doi.org/10.1002/9781118416426.ch64

Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. / Hayashi, Masanori; Loeb, David M.; Chen, Allen R.

Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2 Wiley Blackwell, 2016. p. 768-784.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hayashi, M, Loeb, DM & Chen, AR 2016, Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. in Thomas' Hematopoietic Cell Transplantation: Fifth Edition. vol. 2-2, Wiley Blackwell, pp. 768-784. https://doi.org/10.1002/9781118416426.ch64
Hayashi M, Loeb DM, Chen AR. Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. In Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2. Wiley Blackwell. 2016. p. 768-784 https://doi.org/10.1002/9781118416426.ch64
Hayashi, Masanori ; Loeb, David M. ; Chen, Allen R. / Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. Thomas' Hematopoietic Cell Transplantation: Fifth Edition. Vol. 2-2 Wiley Blackwell, 2016. pp. 768-784
@inbook{ca757cfc86b243dc8ba8efb312342b9e,
title = "Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors",
abstract = "The prognosis for recurrent or refractory pediatric solid tumors such as neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, germ cell tumor, osteosarcoma, and Ewing sarcoma is dismal, and few patients have experienced prolonged survival. Most pediatric solid tumor patients are treated with intensive chemotherapy, and most recurrences occur during treatment or within 1 year of its completion. For agents such as melphalan, carmustine, and carboplatin, whose major dose limiting toxicity is myelosuppression, hematopoietic cell transplantation (HCT) may permit 3-10-fold dose escalation. The recognition that patients with bilateral retinoblastoma are at increased risk of developing osteosarcoma implicates the RB1 gene in the pathogenesis of osteosarcoma. The role of allogeneic HCT in pediatric solid tumors is being explored. Allogeneic transplantation carries the risk of graft-versus-host disease (GVHD), but its potential benefits include the absence of tumor cells in the graft and perhaps an immunologic antitumor effect.",
keywords = "Desmoplastic small round cell tumor, Ewing sarcoma, Graft-versus-host disease, Hematopoietic cell transplantation, Neuroblastoma, Osteosarcoma, Pediatric solid tumors, Retinoblastoma, Rhabdomyosarcoma, Wilms tumor",
author = "Masanori Hayashi and Loeb, {David M.} and Chen, {Allen R.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/9781118416426.ch64",
language = "English (US)",
isbn = "9781118416006",
volume = "2-2",
pages = "768--784",
booktitle = "Thomas' Hematopoietic Cell Transplantation",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors

AU - Hayashi, Masanori

AU - Loeb, David M.

AU - Chen, Allen R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The prognosis for recurrent or refractory pediatric solid tumors such as neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, germ cell tumor, osteosarcoma, and Ewing sarcoma is dismal, and few patients have experienced prolonged survival. Most pediatric solid tumor patients are treated with intensive chemotherapy, and most recurrences occur during treatment or within 1 year of its completion. For agents such as melphalan, carmustine, and carboplatin, whose major dose limiting toxicity is myelosuppression, hematopoietic cell transplantation (HCT) may permit 3-10-fold dose escalation. The recognition that patients with bilateral retinoblastoma are at increased risk of developing osteosarcoma implicates the RB1 gene in the pathogenesis of osteosarcoma. The role of allogeneic HCT in pediatric solid tumors is being explored. Allogeneic transplantation carries the risk of graft-versus-host disease (GVHD), but its potential benefits include the absence of tumor cells in the graft and perhaps an immunologic antitumor effect.

AB - The prognosis for recurrent or refractory pediatric solid tumors such as neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, germ cell tumor, osteosarcoma, and Ewing sarcoma is dismal, and few patients have experienced prolonged survival. Most pediatric solid tumor patients are treated with intensive chemotherapy, and most recurrences occur during treatment or within 1 year of its completion. For agents such as melphalan, carmustine, and carboplatin, whose major dose limiting toxicity is myelosuppression, hematopoietic cell transplantation (HCT) may permit 3-10-fold dose escalation. The recognition that patients with bilateral retinoblastoma are at increased risk of developing osteosarcoma implicates the RB1 gene in the pathogenesis of osteosarcoma. The role of allogeneic HCT in pediatric solid tumors is being explored. Allogeneic transplantation carries the risk of graft-versus-host disease (GVHD), but its potential benefits include the absence of tumor cells in the graft and perhaps an immunologic antitumor effect.

KW - Desmoplastic small round cell tumor

KW - Ewing sarcoma

KW - Graft-versus-host disease

KW - Hematopoietic cell transplantation

KW - Neuroblastoma

KW - Osteosarcoma

KW - Pediatric solid tumors

KW - Retinoblastoma

KW - Rhabdomyosarcoma

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=84979917569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979917569&partnerID=8YFLogxK

U2 - 10.1002/9781118416426.ch64

DO - 10.1002/9781118416426.ch64

M3 - Chapter

AN - SCOPUS:84979917569

SN - 9781118416006

VL - 2-2

SP - 768

EP - 784

BT - Thomas' Hematopoietic Cell Transplantation

PB - Wiley Blackwell

ER -